SEARCH
Search Details
Kudo Akihiko
| Institute for the Promotion of Business-Regional Collaboration | Specially Appointed Assistant Professor |
Career
■ CareerCareer
- Apr. 2025 - Present
Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Department of Neurology, 特任助教 - Apr. 2021 - Mar. 2024
Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Department of Neurology, 博士課程 - Apr. 2020 - Mar. 2021
Hokkaido University Hospital, Neurology, Clinical Fellow - Apr. 2018 - Mar. 2020
市立函館病院, 神経内科, 医員 - Apr. 2017 - Mar. 2018
Hokkaido University Hospital, Neurology, Clinical Fellow - Apr. 2015 - Mar. 2017
JA北海道厚生連帯広厚生病院, 初期研修医
Research activity information
■ Awards■ Papers
- Mitochondrial Dysfunction in Digenic TBP/STUB1 Spinocerebellar Ataxia
Kazuki Yamada; Shunsuke Ogata; Hiroaki Yaguchi; Shintaro Fujii; Taichi Nomura; Akihiko Kudo; Katsuki Eguchi; Hisashi Uwatoko; Shinichi Shirai; Ikuko Takahashi‐Iwata; Masaaki Matsushima; Kohei Hamanaka; Satoko Miyatake; Ichizo Nishino; Yu‐ichi Goto; Naomichi Matsumoto; Ichiro Yabe
Movement Disorders Clinical Practice, 21 Sep. 2026
Scientific journal - A Novel Presenilin‐1 Variant (p.Phe283Val) in Early‐Onset Mild Cognitive Impairment With Striatal Amyloid Accumulation
Ikuko Takahashi‐Iwata; Akihiko Kudo; Taichi Nomura; Shintaro Fujii; Katsuki Eguchi; Hisashi Uwatoko; Shinichi Shirai; Masaaki Matsushima; Hiroaki Yaguchi; Takashi Ozaki; Yuichi Nakamura; Takahiro A. Kato; Norikazu Hara; Takeshi Ikeuchi; Ichiro Yabe
Neurology and Clinical Neuroscience, 16 Sep. 2026
Scientific journal - Diagnostic delay and onset-anchored clinical milestones in progressive supranuclear palsy: a japanese single-center retrospective cohort study.
Kazuhiro Horiuchi; Shuntaro Nakamura; Kaede Ishikawa; Sumire Nunomura; Kazuki Yamada; Takashi Inoue; Kei Oiwa; Shintaro Fujii; Yuki Oshima; Akihiko Kudo; Ichiro Yabe
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47, 7, 24 Jun. 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Progressive supranuclear palsy (PSP) causes falls, dysphagia, pneumonia, fractures, and death, but routine-care timelines and diagnostic-delay survival analyses remain limited. METHODS: We retrospectively studied 68 patients with probable PSP at a Japanese single center. Outcomes were intervals from symptom onset to first visit, probable PSP diagnosis, aspiration pneumonia admission, fracture hospitalization, and death. Patients were grouped by the median onset-to-diagnosis interval (1005.5 days). Survival was analyzed from onset and diagnosis. Sensitivity analyses modeled delay continuously and using 24-, 36-, and 48-month cut-offs; competing risks used Aalen-Johansen estimates. RESULTS: Screening identified 81 patients; 68 remained after chart review. Median onset-to-first visit and onset-to-diagnosis intervals were 24.8 and 33.0 months. Among observed events, median onset-to-aspiration pneumonia admission and onset-to-death intervals were 58.8 and 62.2 months; median diagnosis-to-death among deceased patients was 27.1 months. Death occurred in 26/68 patients (38.2%). Early and Delayed groups had identical death counts (13/34 each), but onset-origin survival differed (log-rank p=0.0013), whereas diagnosis-origin survival did not (p=0.8657). Sensitivity analyses showed the same onset-origin pattern. CONCLUSIONS: Diagnostic delay was substantial, and severe outcomes accumulated over several years. Survival differences by delay group depended on time origin, censoring, and residual selection, and should not be interpreted causally. These timelines may support surveillance and anticipatory care planning in PSP. - Association between the peptide spectrum match values of LGI1, ADAM22, ADAM23 and DLG4 in the immunoprecipitation products of five autoimmune encephalitis cases with LGI1 antibody: A case series.
Akihiko Kudo; Hiroaki Yaguchi; Masashi Watanabe; Taichi Nomura; Hidehisa Takahashi; Keiko Tanaka; Shigetsugu Hatakeyama; Ichiro Yabe
Internal medicine (Tokyo, Japan), 18 Jun. 2026, [Peer-reviewed], [Lead author], [Domestic magazines]
English, Scientific journal, Background LGI1 antibody is one of the most important antibodies associated with autoimmune encephalitis. A biological biomarker for assessing disease severity in LGI1 antibody-associated encephalitis has not yet been established. In this study, we used serum and cerebrospinal fluid (CSF) from patients with LGI1 antibody-positive encephalitis to immunoprecipitate antigens from mouse brain tissue, and the immunoprecipitation (IP) products were subsequently analyzed using mass spectrometry (IP-shotgun proteomics). Methods Five patients with LGI1 antibody-positive cases were included in the patient group. The control group comprised healthy individuals, those with idiopathic normal pressure hydrocephalus, and NMDAR antibody-positive cases. IP-shotgun proteomics was performed for each sample, and specific amino acid sequences identified in the immunoprecipitated products were quantified as peptide spectrum match (PSM) values. We analyzed the PSM values of LGI1 and its binding partners, ADAM22, ADAM23, and DLG4. Results The PSM values of LGI1, ADAM22, and ADAM23 were significantly higher in IP products using sera and CSF from patients with AE with LGI1 antibody than in those from the control group. The most severe case showed the highest PSM values for LGI1, ADAM22, ADAM23, and DLG4 in both serum and CSF, and the mildest case showed the lowest PSM values for these proteins. Conclusion In LGI1 antibody-positive cases, the PSM values of LGI1, ADAM22, ADAM23, and DLG4, which form a complex with LGI1, were higher than those in the control group. Further studies are required to determine whether these PSM values have diagnostic utility and can thus serve as biomarkers of disease severity. - Early respiratory decline around diagnosis and short-term post-landmark outcomes in amyotrophic lateral sclerosis: a 6-month landmark cohort study.
Kazuhiro Horiuchi; Shuntaro Nakamura; Kaede Ishikawa; Sumire Nunomura; Kazuki Yamada; Takashi Inoue; Kei Oiwa; Shintaro Fujii; Yuki Oshima; Akihiko Kudo; Ichiro Yabe
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 47, 7, 08 Jun. 2026, [International Magazine]
English, Scientific journal, BACKGROUND: In amyotrophic lateral sclerosis (ALS), respiratory decisions rely on serial trends rather than a single value. We evaluated whether early respiratory decline around diagnosis provides prognostic information in a real-world landmark framework. METHODS: This single-center retrospective cohort screened 94 consecutive patients diagnosed between April 2019 and December 2025. A 6-month landmark was used. Early decline was estimated from %FVC values between - 30 and + 180 days around diagnosis. The primary model included age and early %FVC decline; robustness analyses included time-varying Cox, piecewise Cox, RMST, included-vs-excluded comparison, death-only analysis, and slope-quality filtering. RESULTS: Of 94 screened patients, 62 met baseline eligibility, 56 had calculable early slope, and 45 entered the landmark cohort; 28 post-landmark composite events occurred. In the Cox model, faster early %FVC decline was associated with higher hazard of death or invasive mechanical ventilation via tracheostomy (HR 1.33 per 1%/month faster decline, 95% CI 1.14-1.55, p < 0.001). PH diagnostics suggested non-proportionality (%FVC p = 0.031; NIV p = 0.034 in the expanded model), so this HR was interpreted as an average follow-up association and complemented by PH-robust analyses. The signal was stronger early than late, remained consistent in a death-only analysis, and favored the slower-decline group by RMST at 24 and 36 months. CONCLUSIONS: In this selected measurement-capable landmark cohort, early respiratory decline provided a clinically meaningful short-to-medium term prognostic signal for post-landmark adverse outcomes. External validation is required before broader generalization beyond measurement-capable landmark populations. - Nationwide screening identifies an expanded clinical spectrum of anti-KLHL11 antibody-associated neurologic disease in Japan.
Pan J; Yaguchi H; Kudo A; Fujii S; Sato H; Yamada K; Uwatoko H; Yang J; Nomura T; Eguchi K; Shirai S; Takahashi-Iwata I; Matsushima M; Okamoto T; Akanuma H; Adachi S; Ishiguro T; Kuwahara H; Tanaka K; Kimura A; Hisahara S; Kanai K; Misawa S; Shimohata T; Takahashi Y; Mizusawa H; Yabe I
Journal of neurology, 19 May 2026
Scientific journal,Objective
To define the clinical spectrum and treatment responses of anti-Kelch-like protein 11 (KLHL11) IgG-associated neurological syndromes by screening a large, expanded cohort of patients with suspected autoimmune cerebellar ataxia (ACA), autoimmune encephalitis (AE), and related neurological disorders.Methods
In this retrospective, observational study, serum samples from 930 patients collected from over 100 medical institutions across Japan between 2002 and 2025 were screened. The study population was categorized into five cohorts: cerebellar ataxia (CA) of unknown etiology (n = 778), AE (n = 49), brainstem encephalitis (n = 2), myelitis (n = 12), and multiple system atrophy (MSA) (n = 89). Anti-KLHL11 antibodies were detected using a fixed cell-based assay with HEK293T cells. Cerebrospinal fluid was analyzed in all serum-positive cases.Results
Anti-KLHL11 antibodies were identified in four cases, three males and one female with a mean onset age > 60 years, all showing dual positivity in serum and cerebrospinal fluid. The clinical phenotypes consisted of predominantly CA (n = 2), combined limbic encephalitis (LE) and CA (n = 1), and isolated LE associated with small-cell lung cancer (n = 1). Notably, none of the cases were associated with testicular tumor. While typical paraneoplastic presentations were observed, one patient had no detectable malignancy and improved with immunotherapy alone, and another showed neurological recovery following treatment of a non-testicular tumor. Anti-KLHL11 antibodies were absent in all disease controls with MSA.Conclusions
Expanding our initial findings, this nationwide study indicates that anti-KLHL11 antibody-associated ACA and AE are rare but increasingly recognized in Japan and may be under-recognized globally. The clinical spectrum of anti-KLHL11 antibody-associated neurological diseases is broad, including females and individuals without a detectable testicular tumor. Importantly, patients presenting with AE may show more favorable responses to immunotherapy or tumor-directed treatment than those with isolated CA, highlighting the importance of early recognition and phenotype-specific management. - Prevalence and profiles of clinically diagnosed autoimmune cerebellar ataxia in a Japanese nationwide survey.
Shintaro Fujii; Hiroaki Yaguchi; Akihiko Kudo; Katsuki Eguchi; Taichi Nomura; Hiroshi Hayashi; Keiko Tanaka; Makoto Yoneda; Akio Kimura; Takayoshi Shimohata; Yuji Takahashi; Hidehiro Mizusawa; Ichiro Yabe
Journal of neurology, 273, 4, 17 Mar. 2026, [International Magazine]
English, Scientific journal, BACKGROUND: Autoimmune cerebellar ataxia (ACA) is a potentially treatable cause of cerebellar dysfunction, but remains underrecognized because of diagnostic challenges, including limited access to autoantibody testing and heterogeneous clinical presentations. We aimed to describe the clinical and laboratory characteristics of patients with clinically diagnosed ACA (cdACA) in Japan, based on expert diagnoses, and evaluate associations between clinical factors and response to immunotherapy. METHODS: This study was a retrospective, multi-center, descriptive study based on a two-step nationwide survey. We inquired at facilities accredited by the Japanese Society of Neurology about the number of patients with cdACA. Furthermore, we asked the facilities with cdACA experience for clinical information. RESULTS: Of 92 cdACA patients, 96.7% had isolated/predominant cerebellar symptoms. Autoantibodies associated with ACA were detected in 47 (51.1%) patients, with glutamic acid decarboxylase (GAD) antibodies being most frequent. 25 (27.2%) patients had concomitant cancer. Among 80 patients who received immunotherapy, 53 (66.2%) responded positively. Responders were more often female (p = 0.006), and had shorter median time to treatment (71 vs 344 days, p = 0.010) and lower CSF protein (40.65 vs 71.05 mg/dL, p = 0.003). Patients without malignancy responded more frequently (p = 0.006). CONCLUSION: This nationwide study provides the first real-world insights into the clinical characteristics and management of cdACA in Japan. Although these findings should be interpreted with caution due to diagnostic heterogeneity and the retrospective study design, some patients with concomitant cancer may also show functional improvement following immunotherapy. In the future, there should be further accumulation of ACA cases and the establishment of diagnostic criteria for ACA. - Limited-Stage Small-Cell Lung Cancer With Severe Paraneoplastic Limbic Encephalitis Successfully Treated With Chemoradiotherapy Followed by Immune Checkpoint Inhibitor Maintenance Therapy: A Case Report.
Daisuke Morinaga; Hidenori Kitai; Hanko Sato; Doppo Fukui; Wataru Harabayashi; Yukiko Yoshida; Shotaro Ito; Yuta Takashima; Megumi Furuta; Akihiko Kudo; Shintaro Fujii; Hisashi Uwatoko; Hiroaki Yaguchi; Keiko Tanaka; Ichiro Yabe; Jun Sakakibara-Konishi; Satoshi Konno
Clinical lung cancer, 27, 2, 121, 125, Mar. 2026, [International Magazine]
English, Scientific journal - Contrasting Outcomes in Two Cases of Anti-contactin-associated Protein-like 2 Autoimmune Encephalitis.
Kazuki Yamada; Hiroaki Yaguchi; Shuntaro Nakamura; Kazuhiro Horiuchi; Shintaro Fujii; Taichi Nomura; Akihiko Kudo; Kenta Tasaki; Makoto Hara; Hideto Nakajima; Ichiro Yabe
Internal medicine (Tokyo, Japan), 13 Nov. 2025, [Domestic magazines]
English, Scientific journal, We herein report two cases of anti-contactin-associated protein-like 2 (CASPR2) autoimmune encephalitis in men in their 70s. Both patients presented with seizures and psychiatric symptoms that required sedation and mechanical ventilation. The treatment included high-dose intravenous methylprednisolone, plasma exchange, and rituximab. One patient fully recovered (modified Rankin Scale [mRS] score 0), whereas the other remained severely disabled (mRS score 5). This difference in outcome may be attributed to the time from symptom onset to treatment initiation. These cases highlight the importance of an early diagnosis and timely immunotherapy for anti-CASPR2 autoimmune encephalitis. - Leukoencephalopathy with primary familial brain calcification: A rare phenotype associated with a novel SLC20A2 frameshift.
Kudo A; Yaguchi H; Nomura T; Uwatoko H; Shirai S; Takahashi-Iwata I; Matsushima M; Yamada T; Yabe I
Clinical neurology and neurosurgery, 22 Oct. 2025, [Peer-reviewed], [Lead author]
Scientific journal - Trends in Invasive Interventions and Risk Factors for Early Critical Events in Multiple System Atrophy.
Monami Tarisawa; Masaaki Matsushima; Akihiko Kudo; Taichi Nomura; Hisashi Uwatoko; Shinichi Shirai; Ikuko Takahashi-Iwata; Ken Sakushima; Hiroaki Yaguchi; Isao Yokota; Naoki Nishimoto; Jun Sawada; Takeshi Matsuoka; Haruo Uesugi; Naoya Minami; Kazuya Sako; Asako Takei; Shin Hisahara; Yasuhiro Kanatani; Akiko Tamakoshi; Norihiro Sato; Ichiro Yabe
Cerebellum (London, England), 24, 5, 152, 152, 06 Sep. 2025, [International Magazine]
English, Scientific journal, Multiple system atrophy (MSA) is a progressive, adult-onset neurodegenerative disorder involving autonomic failure, cerebellar ataxia, and parkinsonism. Patients often require invasive interventions, such as gastrostomy or tracheostomy, and sudden death is common. This study aimed to elucidate patterns of invasive treatment and identify risk factors for tracheostomy or sudden death within 5 years of onset. In total, 214 patients diagnosed with MSA between November 2014 and October 2024 across 66 institutions in Hokkaido were enrolled in the Hokkaido Rare Disease Consortium for MSA (HoRC-MSA). Patients were grouped by clinical course and interventions. We analyzed use of invasive procedures, including enteral nutrition via gastrostomy, enterostomy, esophagostomy, nasogastric tube insertion, central venous nutrition, tracheostomy, and ventilator support. Multivariable analyses were performed to compare patients with and without early critical events, defined as tracheostomy or sudden death within 5 years of disease onset. Invasive procedures were performed in 63.1% of patients. Patients receiving enteral nutrition and tracheostomy had prolonged survival. Early events correlated with older onset age (mean, 65.9 years), orthostatic hypotension, stridor, and an elevated apnea-hypopnea index (median, 32.45). Patients with preserved activities of daily living (ADL) in the Unified MSA Rating Scale part Ⅳ also had an increased risk of early critical events. Autonomic dysfunction, sleep-disordered breathing, and vocal cord impairment predict key risk factors for early mortality in patients with MSA. Monitoring is necessary, regardless of preserved ADL. The impact of invasive interventions on quality of life should be further explored. - Efficacy of early rituximab treatment in anti-mGluR1 encephalitis: a case report.
Kazuki Yamada; Hiroaki Yaguchi; Shuntaro Nakamura; Kazuhiro Horiuchi; Shintaro Fujii; Taichi Nomura; Akihiko Kudo; Akira Takekoshi; Nobuaki Yoshikura; Akio Kimura; Takayoshi Shimohata; Ichiro Yabe
BMC neurology, 25, 1, 319, 319, 04 Aug. 2025, [International Magazine]
English, Scientific journal, BACKGROUND: Anti-mGluR1 encephalitis is a form of autoimmune encephalitis, with limited reports globally and only two cases reported from Japan. There are uncertainties regarding the optimal immunosuppressive agents and individual drug responses. Herein, we report a case of anti-mGluR1 encephalitis from Japan, notable for a favorable outcome after an early rituximab initiation and an observed increase in cerebellar blood flow during the early disease stages. CASE PRESENTATION: The patient was a 65-year-old woman who experienced dizziness for 3 months, followed by worsening gait instability. She was referred to our department due to progressive difficulty standing and walking. Neurological examination revealed dysarthria, severe cerebellar ataxia, and impaired performance on the finger-to-nose and knee-to-heel tests. Blood tests were negative for rheumatologic autoantibodies, and cerebrospinal fluid (CSF) analysis showed a cell count of 4/µL and a protein level of 40.0 mg/dL. However, the IgG index was elevated at 1.35, and oligoclonal bands were positive. Brain magnetic resonance imaging showed no abnormalities, but ¹²³I-iodoamphetamine single-photon emission computed tomography revealed mild hyperperfusion in the bilateral cerebellar hemispheres. Based on the clinical presentation, immune-mediated cerebellar ataxia was suspected. The patient was treated with intravenous methylprednisolone, oral prednisolone, and intravenous immunoglobulin. Further diagnostic testing using tissue- and cell-based assays detected mGluR1 antibodies in pretreatment serum and CSF, confirming the diagnosis of anti-mGluR1 encephalitis. As the initial treatment was insufficient, rituximab was administered, leading to significant improvement, including the ability to walk unaided. At the most recent follow-up, >6 months postonset, she showed no symptom progression or cerebellar atrophy. CONCLUSIONS: We experienced a case of anti-mGluR1 encephalitis with increased cerebellar blood flow, where early RTX administration led to a favorable outcome. Its early use, as an acute treatment and for maintenance, may help prevent recurrence and contribute to a positive prognosis. - Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study.
Shintaro Fujii; Hiroaki Yaguchi; Akihiko Kudo; Katsuki Eguchi; Taichi Nomura; Yukihiro Hamada; Atsuki Hirai; Yuta Fukumoto; Yuko Yamagishi; Makoto Yoneda; Keiko Tanaka; Akio Kimura; Kazufumi Tsuzaka; Yoshitaka Nagai; Ichiro Yabe
Journal of neurology, 272, 4, 282, 282, 22 Mar. 2025, [International Magazine]
English - The importance of early immunotherapy in anti-GluK2 antibody-positive autoimmune cerebellar ataxia: A case report.
Yuto Takeishi; Hiroaki Yaguchi; Akihiko Kudo; Shintaro Fujii; Ikuko Iwata; Taichi Nomura; Mamiko Anada; Kosuke Iwami; Masanao Yoshino; Daiki Tanaka; Keiichi Mizushima; Hisashi Uwatoko; Shinichi Shirai; Masaaki Matsushima; Akio Kimura; Keiko Tanaka; Ichiro Yabe
Journal of the neurological sciences, 467, 123306, 123306, 15 Dec. 2024, [International Magazine]
English - Anti-Tr/DNER Antibody-associated Paraneoplastic Neurological Syndrome Presenting Limbic Encephalitis with Anaplastic Large Cell Lymphoma: A Case Report.
Shintaro Fujii; Hiroaki Yaguchi; Ikuko Takahashi-Iwata; Takashi Inoue; Monami Tarisawa; Taichi Nomura; Akihiko Kudo; Hisashi Uwatoko; Shinichi Shirai; Masaaki Matsushima; Riku Miyaishi; Noriyuki Otsuka; Keiko Tanaka; Koji Taniguchi; Masato Takahashi; Shinya Tanaka; Ichiro Yabe
Internal medicine (Tokyo, Japan), 12 Dec. 2024, [Domestic magazines]
English, Scientific journal, An 82-year-old man presented with acute progressive disturbance of consciousness. We suspected autoimmune limbic encephalitis because of abnormal magnetic resonance imaging findings in the bilateral temporal lobes and cerebrospinal fluid pleocytosis. The patient tested positive for anti-Tr/Delta/Notch-like epidermal growth factor-related receptor (DNER) antibodies, and a tissue biopsy revealed complications of anaplastic large cell lymphoma. Typically, anti-Tr/DNER antibody-associated paraneoplastic neurological syndrome presents with cerebellar ataxia and is complicated by Hodgkin lymphoma (HL). However, there are rare cases that present only with LE and are complicated by tumors other than HL; therefore, aggressive antibody measurement and search for tumors are important. - Muscle vasculitis in patients with polymyalgia rheumatica; three case series.
Haruka Moriya; Yuichiro Fujieda; Yuta Inoue; Kenichi Miyamoto; Mamiko Anada; Daiki Tanaka; Akihiko Kudo; Megumi Abe; Azusa Nagai; Ryo Hisada; Michihito Kono; Masaru Kato; Olga Amengual; Yoshihiro Matsuno; Ichiro Yabe; Tatsuya Atsumi
Modern rheumatology case reports, 09 Dec. 2024, [International Magazine]
English, Scientific journal, Polymyalgia rheumatica (PMR) is a common inflammatory disorder characterized by myalgia/stiffness in proximal hip and shoulder girdle, elevated C reactive protein (CRP) and erythrocyte sedimentation rate (ESR), but its pathogenesis is not fully elucidated. We report three cases of PMR who do not respond adequately to standard treatment. Those patients had typical symptoms of myalgia and muscle weakness, with elevated CRP in absence of creatine kinase elevation. Muscle specimen showed the findings of vasculitis in all cases, therefore muscular limited vasculitis (MLV) may be an underlying pathology in PMR in those refractory cases. - Pretreatment pathology study in anti-LGI1 encephalitis.
Kazuki Yamada; Hiroaki Yaguchi; Kaede Ishikawa; Daiki Tanaka; Yuki Oshima; Keiichi Mizushima; Shintaro Fujii; Taichi Nomura; Akihiko Kudo; Hisashi Uwatoko; Shinichi Shirai; Ikuko Takahashi-Iwata; Masaaki Matsushima; Riku Miyaishi; Noriyuki Otsuka; Zen-Ichi Tanei; Shigeru Yamaguchi; Keiko Tanaka; Koji Taniguchi; Shinya Tanaka; Ichiro Yabe
Journal of the neurological sciences, 466, 123258, 123258, 15 Nov. 2024, [International Magazine]
English - The Movement Disorder Society Criteria: Its Clinical Usefulness in Multiple System Atrophy.
Monami Tarisawa; Masaaki Matsushima; Akihiko Kudo; Ken Sakushima; Yasuhiro Kanatani; Naoki Nishimoto; Jun Sawada; Takeshi Matsuoka; Shin Hisahara; Haruo Uesugi; Naoya Minami; Kazuya Sako; Asako Takei; Akiko Tamakoshi; Norihiro Sato; Hidenao Sasaki; Ichiro Yabe
Internal medicine (Tokyo, Japan), 63, 21, 2903, 2912, 01 Nov. 2024, [Domestic magazines]
English, Scientific journal, Objective In 2022, Wenning et al. proposed the Movement Disorder Society Criteria (MDS criteria) for the Diagnosis of Multiple System Atrophy (MSA). These criteria were expected to provide useful alternatives to the second consensus statement. We examined trends in these diagnostic criteria. Methods We used patient data registered with the Hokkaido Rare Disease Consortium for Multiple System Atrophy, which has been recruiting patients with MSA through medical facilities in Hokkaido since November 2014. Patients were evaluated according to the MDS criteria based on neurological examinations and imaging findings at three separate times: the first evaluation, the time of enrollment (diagnosis), and the most recent evaluation (final evaluation). Results The MDS criteria were examined in 68 of 244 patients enrolled between November 2014 and July 2022. At the initial evaluation, the classifications were as follows: clinically established (n=27; 39.7%); clinically probable (n=13; 19.1%); possible prodromal (n=12; 17.6%); and negative [did not meet criteria (n=16; 23.5%)]. At the time of diagnosis, the classifications were as follows: clinically established (n=45; 66.2%); clinically probable (n=12; 17.6%); possible prodromal (n=4; 5.9%); and negative (n=7; 10.3%). At the final evaluation, the classifications were as follows: clinically established (n=52; 76.5%); clinically probable (n=9; 13.2%); possible prodromal (n=2; 2.9%); and negative (n=5; 7.4%). Conclusion We were able to clarify the changes in the criteria values and transition of patients due to the clarification of imaging and supportive findings in the MDS criteria. - Nonspecific inflammatory pseudotumor of the maxillary and temporal fossa: a study of seven cases.
Wataru Kakuguchi; Yuichi Ashikaga; Yasuhito Moritani; Shintaro Nakano; Naohiro Ogawa; Rieko Yoshitatsu; Aya Yanagawa-Matsuda; Nako Maishi; Akihiko Kudo; Nanase Okazaki; Yuji Nakamaru; Ichiro Yabe; Yoshihiro Matsuno; Yoichi Ohiro
Oral surgery, oral medicine, oral pathology and oral radiology, 138, 4, 494, 501, Oct. 2024, [International Magazine]
English, Scientific journal, OBJECTIVE: Inflammatory pseudotumor (IPT) is a rare, locally aggressive, benign neoplasm of unknown etiology. Because of its aggressive clinical behavior and locally destructive or infiltrative features, it may be mistaken for a malignant tumor. Approximately 5%-44% of extrapulmonary IPT occur in the head and neck, primarily affecting the orbit. STUDY DESIGN: Between 2008 and 2021, our hospital received referrals for seven patients (three men and four women, aged 42-73 years) with pain, swelling, mass, and trismus. Computed tomography, magnetic resonance imaging, and biopsy were performed on all patients to diagnose IPT. RESULTS: Of the seven patients, four received low-dose prednisolone (PSL), one underwent surgery, and two were left untreated. The IPT disappeared in one of the two untreated cases, whereas it improved and later deteriorated in the other. The surgical patient had no recurrence. Low-dose PSL was effective in two patients; however, high-dose PSL and immunosuppressants were required in the remaining two cases owing to infiltration into each orbit or brain region. CONCLUSIONS: Low-dose PSL treatment was applicable in IPT cases affecting the maxillary to temporal fossa region, wherein symptoms did not improve without treatment. However, when low-dose PSL was ineffective, high-dose PSL and immunosuppressants were required. - FGF14 GAA repeat expansion and ZFHX3 GGC repeat expansion in clinically diagnosed multiple system atrophy patients.
Masaaki Matsushima; Hiroaki Yaguchi; Eriko Koshimizu; Akihiko Kudo; Shinichi Shirai; Takeshi Matsuoka; Shigehisa Ura; Atsushi Kawashima; Toshiyuki Fukazawa; Satoko Miyatake; Naomichi Matsumoto; Ichiro Yabe
Journal of neurology, 271, 6, 3643, 3647, Jun. 2024, [International Magazine]
English - Reliability of the unified multiple system atrophy rating scale using the telephone.
Masaaki Matsushima; Azusa Nagai; Rie Nomachi; Akihiko Kudo; Katsuki Eguchi; Masahiro Wakita; Shinichi Shirai; Ikuko Iwata; Kazuhiro Horiuchi; Takeshi Matsuoka; Shigehisa Ura; Hideki Houzen; Ichiro Yabe
Clinical neurology and neurosurgery, 237, 108147, 108147, Feb. 2024, [International Magazine]
English, Scientific journal, OBJECTIVE: The unified multiple system atrophy rating scale (UMSARS) was used to evaluate various symptoms of multiple system atrophy (MSA). And UMSARS part 1 was originally developed for use in interviews, but the need for telemedicine is increasing in COVID-19 pandemic. The purpose of this study is to evaluate the reliability of the UMSARS part 1 telephone survey. METHODS: Thirty-two MSA patients took the UMSARS part 1 face-to-face, followed by two more telephone evaluations. Intraclass correlation coefficients (ICC) and Cronbach's alpha (α) coefficients were calculated, and the inter-rater reliability was determined. At the same time, we asked about the problems in COVID-19 pandemic. RESULTS: The study participants included 15 men and 17 women with mean age of 67.1 years (SD, 8.3). For the total UMSARS part 1 score, the inter-rater ICC and Cronbach's α coefficient were 0.89 to 0.92, and 0.84 to 0.87, respectively. More than half of the items had a relatively high ICC. Cronbach's α coefficients were more than 0.7 for all items. Changes that occurred in COVID-19 pandemic included reduced outings and lack of rehabilitation in about half of the cases. CONCLUSION: The UMSARS part 1 has high inter-rater reliability and internal consistency. Evaluation of subjective symptoms showed that some variability could occur. In addition, there was concern about the influence of lack of rehabilitation due to COVID-19 pandemic. - Switching from zonisamide to perampanel improved the frequency of seizures caused by hyperthermia in Dravet syndrome: a case report.
Kazuhiro Horiuchi; Akihiko Kudo; Shuntaro Nakamura; Kazuki Yamada; Takashi Inoue; Shintaro Fujii; Yuki Oshima
Journal of medical case reports, 18, 1, 3, 3, 03 Jan. 2024, [International Magazine]
English, Scientific journal, BACKGROUND: Dravet syndrome is a severe epilepsy disorder characterized by drug-resistant seizures and cognitive dysfunction, often caused by SCN1A gene mutations. It leads to neurodevelopmental delays and motor, behavioral, and cognitive impairments, with a high mortality rate. Treatment options include sodium valproate, clobazam, and newer agents such as cannabidiol and fenfluramine. Zonisamide, which is used in some cases, can cause hyperthermia and oligohydrosis. Herein, we present a case of a patient with Dravet syndrome whose seizures were controlled by treating infections and switching from zonisamide to perampanel. CASE PRESENTATION: A 24-year-old Japanese man with Dravet syndrome presented to our department with aspiration pneumonia. The patient had been treated with valproate, sodium bromide, and zonisamide for a long time. His seizures were triggered by hyperthermia. The patient was experiencing a sustained pattern of hyperthermia caused by infection, zonisamide, and persistent convulsions, which caused a vicious cycle of further seizures. In this case, the control of infection and switching from zonisamide to perampanel improved seizure frequency. CONCLUSION: Dravet syndrome usually begins with generalized clonic seizures in its infancy because of fever and progresses to various seizure types, often triggered by fever or seizure-induced heat due to mutations in the SCN1A gene that increases neuronal excitability. Seizures usually diminish with age, but the heat sensitivity remains. In this case, seizures were increased by repeated infections, and hyperthermia was induced by zonisamide, resulting in status epilepticus. Perampanel, an aminomethylphosphonic acid receptor antagonist, decreased seizures but caused psychiatric symptoms. It was effective in suppressing seizures of Dravet syndrome in this patient. - A retrospective study of autoimmune cerebellar ataxia over a 20-year period in a single institution.
Akihiko Kudo; Hiroaki Yaguchi; Keiko Tanaka; Akio Kimura; Ichiro Yabe
Journal of neurology, 271, 1, 553, 563, Jan. 2024, [Peer-reviewed], [Lead author], [International Magazine]
English, Scientific journal, BACKGROUND: It is important to differentiate autoimmune cerebellar ataxia (ACA) from neurodegenerative CA, but this is sometimes difficult. We performed a retrospective study in a single institution in Japan over a 20-year period to reveal the clinical features of ACA. METHODS: Patients with CA as the primary neurological symptom were enrolled from those admitted to the Department of Neurology, Hokkaido University Hospital between April 2002 and March 2022. ACA was diagnosed retrospectively according to the following criteria: (1) CA being the predominant symptom; (2) identification of cancer within 2 years of onset; (3) improvement in cerebellar symptoms following immunotherapy; and (4) ruling out alternative causes of CA. Patients fulfilling criteria (1), (2), and (4) were classified as paraneoplastic cerebellar degeneration (PCD), while those fulfilling (1), (3), and (4) were classified as non-PCD and enrolled as patients with ACA. Neurodegenerative diseases, e.g., multiple system atrophy (MSA), were confirmed retrospectively based on generally used diagnostic criteria and enrolled. Furthermore, the ACA diagnostic criteria proposed by Dalmau and Graus were applied retrospectively to the ACA patients to examine the validity of the diagnoses. RESULTS: Among the 243 patients with CA, 13 were enrolled as ACA; five were PCD and eight were non-PCD. Eight of these cases met the proposed diagnostic criteria by Dalmau and Graus. MSA was the most prevalent disease among CA patients, with 93 cases. The incidence of cerebellar atrophy was significantly lower in ACA (3/13) than in MSA (92/92). Cerebrospinal fluid (CSF) pleocytosis was significantly more frequent in ACA than in MSA (4/13 vs. 2/55, respectively). However, there was no significant difference in the presence of oligoclonal bands, increased protein in CSF, and laterality differences in ataxia. CONCLUSION: ACA was present in ~ 5% of Japanese CA patients. The absence of cerebellar atrophy, despite the presence of CA, strongly supports ACA over MSA. While CSF pleocytosis was observed more often in ACA, the positivity rate was only ~ 30%. Since ACA is treatable, further studies are needed to identify additional clinical features and accurate diagnostic biomarkers. - Behavioral and histological analyses of the mouse Bassoon p.P3882A mutation corresponding to the human BSN p.P3866A mutation.
Daiki Tanaka; Hiroaki Yaguchi; Kaichi Yoshizaki; Akihiko Kudo; Fumiaki Mori; Taichi Nomura; Jing Pan; Yasuo Miki; Hidehisa Takahashi; Taichi Hara; Koichi Wakabayashi; Ichiro Yabe
Frontiers in neuroscience, 18, 1414145, 1414145, 2024, [International Magazine]
English, Scientific journal, Tauopathy is known to be a major pathognomonic finding in important neurodegenerative diseases such as progressive supranuclear palsy (PSP) and corticobasal degeneration. However, the mechanism by which tauopathy is triggered remains to be elucidated. We previously identified the point mutation c.11596C > G, p.Pro3866Ala in the Bassoon gene (BSN) in a Japanese family with PSP-like syndrome. We showed that mutated BSN may have been involved in its own insolubilization and tau accumulation. Furthermore, BSN mutations have also been related to various neurological diseases. In order to further investigate the pathophysiology of BSN mutation in detail, it is essential to study it in mouse models. We generated a mouse model with the mouse Bassoon p.P3882A mutation, which corresponds to the human BSN p.P3866A mutation, knock-in (KI) and we performed systematic behavioral and histological analyses. Behavioral analyses revealed impaired working memory in a Y-maze test at 3 months of age and decreased locomotor activity in the home cage at 3 and 12 months of age in KI mice compared to those in wild-type mice. Although no obvious structural abnormalities were observed at 3 months of age, immunohistochemical studies showed elevation of Bsn immunoreactivity in the hippocampus and neuronal loss without tau accumulation in the substantia nigra at 12 months of age in KI mice. Although our mice model did not show progressive cognitive dysfunction and locomotor disorder like PSP-like syndrome, dopaminergic neuronal loss was observed in the substantia nigra in 12-month-old KI mice. It is possible that BSN mutation may result in dopaminergic neuronal loss without locomotor symptoms due to the early disease stage. Thus, further clinical course can induce cognitive dysfunction and locomotor symptoms. - Sez6l2 autoimmunity in a large cohort study.
Megumi Abe; Hiroaki Yaguchi; Akihiko Kudo; Azusa Nagai; Shinichi Shirai; Ikuko Takahashi-Iwata; Masaaki Matsushima; Naoko Nakamura; Kenji Isahaya; Yoshihisa Yamano; Shinji Ashida; Takashi Kasai; Keiko Tanaka; Masashi Watanabe; Takeshi Kondo; Hidehisa Takahashi; Shigetsugu Hatakeyama; Akira Takekoshi; Akio Kimura; Takayoshi Shimohata; Ichiro Yabe
Journal of neurology, neurosurgery, and psychiatry, 94, 8, 667, 668, Aug. 2023, [International Magazine]
English - Neutral lipid storage disease with myopathy with a novel homozygous PNPLA2 variant.
Kazuki Yamada; Hiroaki Yaguchi; Megumi Abe; Kaede Ishikawa; Daiki Tanaka; Yuki Oshima; Akihiko Kudo; Hisashi Uwatoko; Shinichi Shirai; Ikuko Takahashi-Iwata; Masaaki Matsushima; Ichizo Nishino; Ichiro Yabe
Clinical neurology and neurosurgery, 228, 107670, 107670, May 2023, [International Magazine]
English, Scientific journal - Rituximab Was Effective in Relieving Symptoms of Isaacs Syndrome: A Case Report.
Kazuhiro Horiuchi; Akihiko Kudo; Takashi Inoue; Shintaro Fujii; Yuki Oshima
Cureus, 14, 10, e30100, Oct. 2022, [International Magazine]
English, Scientific journal, We presented a 23-year-old patient who had experienced neuromyotonia in his left leg. Although he tested negative for anti-LGI1 and anti-CASPR2 antibodies, we diagnosed him with Isaacs syndrome due to myokymic discharges on electromyography and symptoms being relieved by intravenous methylprednisolone (IVMP) and intravenous immunoglobulin (IVIg). IVMP, IVIg, plasma exchange, or cyclosporine treatment did not provide a long-term response; however, rituximab showed long-term improvement. Rituximab should be considered early in the treatment of patients with antibody-negative Isaacs syndrome who are responsive to immunotherapy, including IVMP, IVIg, and plasma exchange, and have long-term symptoms that are hard to control. - Successful Treatment with Rituximab for Granulomatosis with Polyangiitis and Multiple Cranial Neuropathies.
Kazuhiro Horiuchi; Yuki Oshima; Akihiko Kudo
Internal medicine (Tokyo, Japan), 60, 7, 1095, 1099, 01 Apr. 2021, [Domestic magazines]
English, Scientific journal, We herein report a case of granulomatosis with polyangiitis in a 73-year-old man. He had experienced bilateral ptosis, redness of both eyes, right facial weakness, and hearing loss in the right ear for two months. Myeloperoxidase anti-neutrophil cytoplasmic antibody was positive. Corticosteroids and intravenous cyclophosphamide pulse therapy yielded a response. After the fourth pulse of cyclophosphamide, he developed headache, diplopia, restricted left eye movement, right facial palsy, and hearing loss in the right ear. A one-year remission period was achieved by increasing the steroid and rituximab doses. Rituximab was effective against the relapse of granulomatosis with polyangiitis and cranial neuropathy. - MM2 cortical form of sporadic Creutzfeldt-Jakob disease without progressive dementia and akinetic mutism: A case deviating from current diagnostic criteria.
Ikuko Takahashi-Iwata; Ichiro Yabe; Akihiko Kudo; Katsuya Eguchi; Masahiro Wakita; Shinichi Shirai; Masaaki Matsushima; Takanobu Toyoshima; Susumu Chiba; Satoshi Tanikawa; Shinya Tanaka; Katsuya Satoh; Tetsuyuki Kitamoto; Hidenao Sasaki
Journal of the neurological sciences, 412, 116759, 116759, 15 May 2020, [International Magazine]
English
- PMLとCMVの共感染症例の病理学的解析(A case of PML with CMV infection in the brain)
黒田 花音; 種井 善一; 岡崎 ななせ; 工藤 彰彦; 寺島 祐樹; 谷川 聖; 小田 義崇; 津田 真寿美; 矢部 一郎; 田中 伸哉, 日本病理学会会誌, 115, 1, 379, 379, Mar. 2026
(一社)日本病理学会, English - PMLとCMVの共感染症例の病理学的解析(A case of PML with CMV infection in the brain)
黒田 花音; 種井 善一; 岡崎 ななせ; 工藤 彰彦; 寺島 祐樹; 谷川 聖; 小田 義崇; 津田 真寿美; 矢部 一郎; 田中 伸哉, 日本病理学会会誌, 115, 1, 379, 379, Mar. 2026
(一社)日本病理学会, English - 慢性期に免疫療法を行ったSez612抗体陽性自己免疫性小脳失調症の1例
高橋 義秋; 佐々木 諒; 森本 みずき; 木村 暁夫; 下畑 享良; 藤井 信太朗; 工藤 彰彦; 矢口 裕章; 矢部 一郎; 森本 展年, 臨床神経学, 65, 11, 843, 843, Nov. 2025
(一社)日本神経学会, Japanese - Tissue-Based Assayが陽性であった傍腫瘍性辺縁系脳炎の1例
佐藤 凡功; 上床 尚; 岩見 昂亮; 大岩 慧; 山田 一貴; 中村 俊太郎; 岩波 太志; 川北 カイキ; 真島 慧太; 藤井 信太朗; 野村 太一; 工藤 彰彦; 白井 慎一; 岩田 育子; 松島 理明; 矢口 裕章; 森永 大亮; 北井 秀典; 中村 悠一; 山邊 茜; 田中 惠子; 加藤 隆弘; 矢部 一郎, 臨床神経学, 65, 11, 848, 848, Nov. 2025
(一社)日本神経学会, Japanese - 自己免疫性脳炎の疫学と疾患の広がり 自己免疫性運動異常症 自己免疫性小脳失調症を中心に
工藤 彰彦; 矢口 裕章; 藤井 信太朗; 野村 太一; 矢部 一郎, NEUROINFECTION, 30, 1, 48, 53, Sep. 2025
日本神経感染症学会, Japanese - 脊髄小脳失調症1型の自然歴調査研究(第2報)
白井 慎一; 工藤 彰彦; 野村 太一; 上床 尚; 岩田 育子; 松島 理明; 佐久嶋 研; 矢口 裕章; 矢部 一郎, 臨床神経学, 65, Suppl., S318, S318, Sep. 2025
(一社)日本神経学会, Japanese - 自己免疫性脳炎の疫学と疾患の広がり 自己免疫性運動異常症 自己免疫性小脳失調症を中心に
工藤 彰彦; 矢口 裕章; 藤井 信太朗; 野村 太一; 矢部 一郎, NEUROINFECTION, 30, 1, 48, 53, Sep. 2025
日本神経感染症学会, Japanese - 悪性腫瘍と免疫性神経疾患:新たながん治療の時代における脳神経内科医の役割 小脳性運動失調症と悪性腫瘍
工藤 彰彦; 矢口 裕章; 矢部 一郎, 神経免疫学, 30, 1, 111, 111, Aug. 2025
(一社)日本神経免疫学会, Japanese - 脳炎・脳症-2 当院で臨床的に自己免疫性小脳失調症と診断した症例の自己抗体測定、ならびに免疫組織学的検討
藤井 信太朗; 矢口 裕章; 工藤 彰彦; 野村 太一; 上床 尚; 矢部 一郎, 神経免疫学, 30, 1, 182, 182, Aug. 2025
(一社)日本神経免疫学会, Japanese - 亜急性に進行する運動失調及び認知機能低下、パーキンソニズムを呈したSez6l2抗体陽性脳炎の1例
小川 和記; 野本 樹里; 勝元 敦子; 林 幼偉; 藤井 信太朗; 工藤 彰彦; 矢口 裕章; 矢部 一郎; 高橋 祐二, 神経免疫学, 30, 1, 208, 208, Aug. 2025
(一社)日本神経免疫学会, Japanese - GluK2抗体陽性自己免疫性小脳失調症の1例
武石 侑杜; 矢口 裕章; 工藤 彰彦; 藤井 信太朗; 岩田 育子; 穴田 麻眞子; 岩見 昂亮; 芳野 正修; 野村 太一; 木村 暁夫; 田中 惠子; 矢部 一郎, 臨床神経学, 65, 6, 473, 473, Jun. 2025
(一社)日本神経学会, Japanese - KLHL11抗体が陽性であった自己免疫性小脳失調症の1例
藤井 信太朗; 矢口 裕章; 工藤 彰彦; 野村 太一; 上床 尚; 白井 慎一; 岩田 育子; 松島 理明; 津坂 和文; 矢部 一郎, 臨床神経学, 65, 6, 474, 474, Jun. 2025
(一社)日本神経学会, Japanese - 新しい時代の自己免疫性小脳失調症の診断・治療 本邦における自己免疫性小脳失調症の抗体測定体制の確立
矢口 裕章; 工藤 彰彦; 藤井 信太朗; 野村 太一; 矢部 一郎, 神経治療学, 42, 3, 394, 398, May 2025
(一社)日本神経治療学会, Japanese - 血清中のKLHL11抗体が陽性であった自己免疫性小脳失調症の1例
平井 敦樹; 山岸 裕子; 山下 翔子; 谷口 圭子; 福本 雄太; 寒川 真; 桑原 基; 平野 牧人; 藤井 信太郎; 工藤 彰彦; 矢口 裕章; 矢部 一郎; 永井 義隆, 臨床神経学, 65, 2, 169, 169, Feb. 2025
(一社)日本神経学会, Japanese - 亜急性に進行する運動失調及び認知機能低下,パーキンソニズムを呈したSez612抗体陽性脳炎の1例
小川和記; 野本樹里; 勝元敦子; 林幼偉; 藤井信太朗; 工藤彰彦; 矢口裕章; 矢部一郎; 高橋祐二, Neuroimmunology, 30, 1, 2025 - Paraneoplastic cerebellar degeneration-Lambert-Eaton myasthenic syndrome(PCD-LEMS)の小脳性運動失調に対して免疫グロブリン大量静注療法(IVIg)が有効であった1例
川北カイキ; 上床尚; 岩波太志; 佐藤凡功; 真島慧太; 中村俊太郎; 山田一貴; 大岩慧; 藤井信太朗; 野村太一; 工藤彰彦; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 伊藤祥太郎; 古田恵; 矢部一郎, 臨床神経学(Web), 65, 11, 2025 - 脳生検により診断に至った難治性神経好中球病の1例
岩波太志; 山田一貴; 田中大貴; 佐藤凡功; 川北カイキ; 真島慧太; 中村俊太郎; 大岩慧; 野村太一; 工藤彰彦; 上床尚; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 大前敬祐; 氏原匡樹; 山口秀; 種井善一; 田中伸哉; 田中伸哉; 田中伸哉; 矢部一郎, 臨床神経学(Web), 65, 11, 2025 - Tissue-Based Assayが陽性であった傍腫瘍性辺縁系脳炎の1例
佐藤凡功; 上床尚; 岩見昂亮; 大岩慧; 山田一貴; 中村俊太郎; 岩波太志; 川北カイキ; 真島慧太; 藤井信太朗; 野村太一; 工藤彰彦; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 森永大亮; 北井秀典; 中村悠一; 山邊茜; 田中惠子; 田中惠子; 加藤隆弘; 矢部一郎, 臨床神経学(Web), 65, 11, 2025 - 慢性期に免疫療法を行ったSez6l2抗体陽性自己免疫性小脳失調症の1例
高橋義秋; 佐々木諒; 森本みずき; 木村暁夫; 下畑享良; 藤井信太朗; 工藤彰彦; 矢口裕章; 矢部一郎; 森本展年, 臨床神経学(Web), 65, 11, 2025 - Establishment of anti-neural antibody testing system for autoimmune cerebellar ataxia in Japan
矢口裕章; 工藤彰彦; 藤井信太朗; 野村太一; 矢部一郎, 神経治療学(Web), 42, 3, 2025 - Sez6l2 antibodies and cerebellar ataxia.
藤井信太朗; 矢口裕章; 工藤彰彦; 矢部一郎, 月刊脳神経内科, 102, 5, 508, 516, 2025
(有)科学評論社, Japanese - 血清中のKLHL11抗体が陽性であった自己免疫性小脳失調症の1例
平井敦樹; 山岸裕子; 山下翔子; 谷口圭子; 福本雄太; 寒川真; 桑原基; 平野牧人; 藤井信太郎; 工藤彰彦; 矢口裕章; 矢部一郎; 永井義隆, 臨床神経学(Web), 65, 2, 2025 - 新しい時代の自己免疫性小脳失調症の診断・治療 本邦における自己免疫性小脳失調症の抗体測定体制の確立
矢口 裕章; 工藤 彰彦; 藤井 信太朗; 野村 太一; 江口 克紀; 矢部 一郎, 神経治療学, 41, 6, S180, S180, Oct. 2024
(一社)日本神経治療学会, Japanese - 自己免疫性脳炎の診断や治療における脳波検査 自己免疫性脳炎診断と治療方針決定における脳波所見の重要性と今後の課題
矢口 裕章; 野村 太一; 工藤 彰彦; 藤井 信太朗; 矢部 一郎, 臨床神経生理学, 52, 5, 488, 488, Oct. 2024
(一社)日本臨床神経生理学会, Japanese - 自己免疫性脳炎の疫学と疾患の広がり 自己免疫性運動異常症 自己免疫性小脳失調症を中心に
矢口 裕章; 工藤 彰彦; 藤井 信太朗; 野村 太一; 矢部 一郎, NEUROINFECTION, 29, 2, 82, 82, Sep. 2024
日本神経感染症学会, Japanese - 日常臨床において治療可能な自己免疫性/傍腫瘍性神経疾患をいかに見出すか? 特発性小脳性運動失調症に類似する自己免疫性/傍腫瘍性疾患
矢口 裕章; 工藤 彰彦; 矢部 一郎, 神経治療学, 41, 3, 237, 239, May 2024
(一社)日本神経治療学会, Japanese - 自己免疫性運動異常症~自己免疫性小脳失調症を中心に~
矢口裕章; 工藤彰彦; 藤井信太朗; 野村太一; 矢部一郎, Neuroinfection (Web), 29, 2, 2024 - 本邦における自己免疫性小脳失調症の抗体測定体制の確立
矢口裕章; 工藤彰彦; 藤井信太朗; 野村太一; 江口克紀; 矢部一郎, 神経治療学(Web), 41, 6, 2024 - 免疫沈降法とショットガンプロテオミクスによる自己抗体測定方法の開発
工藤彰彦; 矢口裕章; 渡部昌; 藤井信太朗; 野村太一; 上床恵; 上床尚; 白井慎一; 岩田育子; 松島理明; 田中惠子; 高橋秀尚; 畠山鎮次; 矢部一郎, Neuroimmunology, 29, 1, 218, 218, 2024
(一社)日本神経免疫学会, Japanese - Autoimmune cerebellar ataxia similar to idiopathic cerebellar ataxia
矢口裕章; 工藤彰彦; 矢部一郎, 神経治療学(Web), 41, 3, 2024 - 自己免疫性小脳失調症に関連する自己抗体とレジストリ研究
矢口裕章; 工藤彰彦; 藤井信太朗; 野村太一; 矢部一郎, Neuroimmunology, 29, 1, 90, 90, 2024
(一社)日本神経免疫学会, Japanese - 自己免疫性脳炎診断と治療方針決定における脳波所見の重要性と今後の課題
矢口裕章; 矢口裕章; 野村太一; 工藤彰彦; 藤井信太朗; 矢部一郎; 矢部一郎, 臨床神経生理学(Web), 52, 5, 2024 - 日常臨床において治療可能な自己免疫性/傍腫瘍性神経疾患をいかに見出すか? 特発性小脳性運動失調症に類似する自己免疫性/傍腫瘍性疾患
矢口 裕章; 工藤 彰彦; 矢部 一郎, 神経治療学, 40, 6, S99, S99, Oct. 2023
(一社)日本神経治療学会, Japanese - 標準的自己免疫性小脳失調症診療の均てん化を目指す試み
矢口 裕章; 工藤 彰彦; 阿部 恵; 野村 太一; 江口 克紀; 上床 尚; 白井 慎一; 岩田 育子; 松島 理明; 矢部 一郎, 臨床神経学, 63, 5, 327, 327, May 2023
(一社)日本神経学会, Japanese - Case Report; A case of Parkinson’s disease with dementia identified with α-synuclein pathology in the sigmoid colon.
穴田麻眞子; 工藤彰彦; 阿部恵; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 吉田雅; 種井善一; 矢部一郎, 日本内科学会雑誌, 112, 8, 2023 - 自己免疫性小脳失調症に対する免疫沈降法と質量分析法を用いた網羅的自己抗体測定方法の開発
工藤彰彦; 矢口裕章; 渡部昌; 上床尚; 白井慎一; 岩田育子; 松島理明; 高橋秀尚; 畠山鎮次; 矢部一郎, Neuroimmunology, 28, 1, 2023 - 特発性小脳性運動失調症に類似する自己免疫性/傍腫瘍性疾患
矢口裕章; 工藤彰彦; 矢部一郎, 神経治療学(Web), 40, 6, 2023 - 視神経乳頭炎で発症し,髄膜脳炎症状が軽微であった自己免疫性GFAPアストロサイトパチー(GFAP-A)の1例
藤井信太朗; 井上貴司; 足澤萌奈美; 野村太一; 田中大貴; 水島慶一; 工藤彰彦; 阿部恵; 上床尚; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 荻野陽; 矢部一郎, 臨床神経学(Web), 63, 11, 2023 - 本邦における自己免疫性小脳失調症レジストリ作成と診断基準作成の試み
矢口裕章; 工藤彰彦; 野村太一; 江口克紀; 田中恵子; 米田誠; 木村暁夫; 下畑享良; 矢部一郎, 神経治療学(Web), 40, 6, 2023 - 多系統萎縮症新診断基準の有用性の検討
市之川萌奈美; 市之川萌奈美; 松島理明; 工藤彰彦; 佐久嶋研; 西本尚樹; 澤田潤; 松岡健; 南尚哉; 佐光一也; 武井麻子; 久原真; 佐藤典宏; 佐々木秀直; 矢部一郎, 日本神経学会学術大会プログラム・抄録集, 64th, 2023 - 非典型的な症状であるが,seronegative重症筋無力症(SNMG)と考えられた2例
石丸誠己; 布村菫; 穴田麻眞子; 大岩慧; 水島慶一; 佐藤翔紀; 工藤彰彦; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 矢部一郎, 臨床神経学(Web), 62, 4, 2022 - Good症候群を背景に小脳及び脳幹に限局する病変を呈した進行性多巣性白質脳症(PML)の1例
布村菫; 石丸誠己; 穴田麻眞子; 水島慶一; 佐藤翔紀; 工藤彰彦; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 矢部一郎, 臨床神経学(Web), 62, 4, 2022 - 発語失行および劣位半球優位の脳萎縮と血流低下を認めた大脳皮質基底核変性症候群の1例
穴田麻眞子; 石丸誠己; 布村菫; 水島慶一; 工藤彰彦; 佐藤翔紀; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 松島理明; 矢口裕章; 矢部一郎; 大槻美佳, 臨床神経学(Web), 62, 4, 2022 - 髄膜増強像を呈した自己免疫性GFAPアストロサイトパチー(GFAP-A)の1例
布村菫; 水島慶一; 佐藤翔紀; 工藤彰彦; 白井慎一; 岩田育子; 松島理明; 矢口裕章; 矢部一郎, 臨床神経学(Web), 62, 7, 2022 - 世界1例目のSez612抗体陽性小脳性運動失調症の臨床経過
阿部恵; 矢口裕章; 長井梓; 工藤彰彦; 白井慎一; 岩田育子; 松島理明; 矢部一郎, 臨床神経学(Web), 62, 7, 2022 - 免疫介在性小脳失調症における新規自己抗体の検討
工藤彰彦; 矢口裕章; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 水戸泰紀; 田島康敬; 渡部昌; 畠山鎮次; 米田誠; 田中惠子; 矢部一郎, 日本神経学会学術大会プログラム・抄録集, 63rd, 2022 - アルツハイマー病以外の神経変性疾患 5.多系統萎縮症/特発性小脳失調症/遺伝性脊髄小脳変性症
工藤彰彦; 松島理明; 矢部一郎, Geriatric Medicine, 59, 12, 2021 - B症状や末梢神経障害を契機に診断された,クリオグロブリン(CG)血管炎の1例
足澤萌奈美; 大岩慧; 瀬尾祥; 田中大貴; 工藤彰彦; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 原田晋平; 遠藤知之; 矢部一郎, 臨床神経学(Web), 61, 7, 2021 - アイザックス症候群の1例
工藤彰彦; 藤井信太朗; 大嶌祐貴; 堀内一宏; 矢部一郎, 臨床神経学(Web), 61, 1, 2021 - 非定型Logopenic型原発性進行性失語様の言語症状を呈した若年性Alzheimer病の1例
足澤萌奈美; 大岩慧; 瀬尾祥; 田中大貴; 工藤彰彦; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 大槻美佳; 矢部一郎, 臨床神経学(Web), 61, 1, 2021 - 大脳皮質脳炎で再発した抗MOG抗体陽性脳炎の1例
田中大貴; 大岩慧; 瀬尾祥; 足澤萌奈美; 工藤彰彦; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 矢部一郎, 臨床神経学(Web), 61, 7, 2021 - 肥厚性硬膜炎13例の後方視的検討
工藤彰彦; 大岩慧; 瀬尾祥; 足澤萌奈美; 田中大貴; 阿部恵; 江口克紀; 長井梓; 脇田雅大; 白井慎一; 岩田育子; 松島理明; 矢部一郎, 日本神経学会学術大会プログラム・抄録集, 62nd, 2021 - てんかん様発作と脳炎様症状を繰り返した神経核内封入体病の1例
大嶌 祐貴; 工藤 彰彦; 水島 慶一; 芳野 正修; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 谷川 聖; 矢部 一郎; 佐々木 秀直, 臨床神経学, 59, 1, 50, 50, Jan. 2019
(一社)日本神経学会, Japanese - 後遺症を残さず改善した脳静脈洞血栓症の一例
工藤彰彦; 堀内一宏; 丸尾泰則, 臨床神経学(Web), 59, 1, 2019 - てんかん様発作と脳炎様症状を繰り返した神経核内封入体病の1例
大嶌祐貴; 工藤彰彦; 工藤彰彦; 水島慶一; 芳野正修; 佐藤智彦; 長沼亮滋; 上床尚; 白井慎一; 高橋育子; 松島理明; 谷川聖; 矢部一; 佐々木秀直, 臨床神経学(Web), 59, 1, 2019 - 肺炎球菌性髄膜炎に脳血管攣縮が合併した一例
工藤彰彦; 堀内一宏; 丸尾泰則, 臨床神経学(Web), 59, 6, 2019 - 両側大脳半球に病変を呈したRasmussen脳炎の1例
岩見昂亮; 水島慶一; 工藤彰彦; 高橋育子; 大嶌祐貴; 芳野正修; 江口克紀; 脇田雅大; 白井慎一; 松島理明; 山口秀; 越前谷すみれ; 後藤秀輔; 桑原健; 高桑恵美; 武井英博; 矢部一郎; 佐々木秀直, 日本神経学会学術大会プログラム・抄録集, 60th, 2019 - 神経サルコイドーシス26例の後方視的検討
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 西村 洋昭; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 佐々木 秀直, 臨床神経学, 58, Suppl., S243, S243, Dec. 2018
(一社)日本神経学会, English - 脊髄長大病変を呈し抗AQP4抗体陽性であった神経梅毒
水島 慶一; 佐藤 智香; 佐藤 翔紀; 工藤 彰彦; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 森島 穣; 関 俊隆; 寺坂 俊介; 佐々木 秀直, 臨床神経学, 58, Suppl., S452, S452, Dec. 2018
(一社)日本神経学会, Japanese - 急速に両側声帯麻痺をきたし、新規GFAP遺伝子変化を認めたアレキサンダー病
大嶌 祐貴; 佐藤 翔紀; 工藤 彰彦; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 吉田 誠克; 佐々木 秀直, 臨床神経学, 58, Suppl., S455, S455, Dec. 2018
(一社)日本神経学会, Japanese - IVW-MRIが治療効果判定に有用であった中枢神経限局性血管炎
井上 知彦; 水島 慶一; 工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 原田 太以佑; 工藤 與亮; 佐々木 秀直, 臨床神経学, 58, Suppl., S456, S456, Dec. 2018
(一社)日本神経学会, Japanese - 抗NMDAR抗体関連脳炎の既往歴を有する免疫介在性運動ニューロパチーの1例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 西村 洋昭; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 楠 進; 佐々木 秀直, 臨床神経学, 58, 5, 360, 360, May 2018
(一社)日本神経学会, Japanese - 経過中にイレウスを発症した抗PL-7抗体陽性筋症の1例
大嶌 祐貴; 工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 西村 洋昭; 宮本 秀一; 佐々木 秀直, 臨床神経学, 58, 5, 356, 356, May 2018
(一社)日本神経学会, Japanese - 腹臥位での腰仙椎MRIが診断に有用であった脊髄係留症候群の1例
水島 慶一; 佐藤 翔紀; 工藤 彰彦; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 原田 太以佑; 工藤 與亮; 濱内 祝嗣; 関 俊隆; 佐々木 秀直, 臨床神経学, 58, 5, 358, 358, May 2018
(一社)日本神経学会, Japanese - 経過中にイレウスを発症した抗PL-7抗体陽性筋症の1例
大嶌 祐貴; 工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 西村 洋昭; 宮本 秀一; 佐々木 秀直, 臨床神経学, 58, 5, 356, 356, May 2018
(一社)日本神経学会, Japanese - 腹臥位での腰仙椎MRIが診断に有用であった脊髄係留症候群の1例
水島 慶一; 佐藤 翔紀; 工藤 彰彦; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 原田 太以佑; 工藤 與亮; 濱内 祝嗣; 関 俊隆; 佐々木 秀直, 臨床神経学, 58, 5, 358, 358, May 2018
(一社)日本神経学会, Japanese - 抗NMDAR抗体関連脳炎の既往歴を有する免疫介在性運動ニューロパチーの1例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 西村 洋昭; 白井 慎一; 高橋 育子; 松島 理明; 矢部 一郎; 楠 進; 佐々木 秀直, 臨床神経学, 58, 5, 360, 360, May 2018
(一社)日本神経学会, Japanese - 抗NMDAR抗体関連脳炎の既往歴を有する免疫介在性運動ニューロパチーの1例
工藤彰彦; 佐藤翔紀; 佐藤智香; 長沼亮滋; 上床尚; 西村洋昭; 白井慎一; 高橋育子; 松島理明; 矢部一郎; 楠進; 佐々木秀直, 臨床神経学(Web), 58, 5, 2018 - 経過中にイレウスを発症した抗PL-7抗体陽性筋症の1例
大嶌祐貴; 工藤彰彦; 佐藤翔紀; 佐藤智香; 長沼亮滋; 上床尚; 白井慎一; 高橋育子; 松島理明; 矢部一郎; 西村洋昭; 宮本秀一; 佐々木秀直, 臨床神経学(Web), 58, 5, 2018 - 多系統萎縮症様のMRI所見を呈した自己免疫性小脳炎の1例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 西村 洋昭; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 佐々木 秀直, 臨床神経学, 57, 12, 813, 813, Dec. 2017
(一社)日本神経学会, Japanese - 四肢完全麻痺を呈したが長期間の血漿交換療法が奏功した視神経脊髄炎関連疾患の1例
佐藤 智香; 佐藤 翔紀; 工藤 彰彦; 阿部 恵; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 上杉 春雄; 佐々木 秀直, 臨床神経学, 57, 12, 814, 814, Dec. 2017
(一社)日本神経学会, Japanese - ATXN2遺伝子CAGリピート数異常伸長を伴った筋萎縮性側索硬化症の1例
佐藤 翔紀; 工藤 彰彦; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 西村 洋昭; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 佐々木 秀直, 臨床神経学, 57, 12, 816, 816, Dec. 2017
(一社)日本神経学会, Japanese - 中枢神経血管内リンパ腫の5例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 白鳥 聡一; 後藤 秀樹; 加畑 馨; 近藤 健; 佐々木 秀直, 神経治療学, 34, 6, S223, S223, Nov. 2017
日本神経治療学会, Japanese - 中枢神経血管内リンパ腫の5例
工藤 彰彦; 佐藤 翔紀; 佐藤 智香; 長沼 亮滋; 上床 尚; 白井 慎一; 高橋 育子; 松島 理明; 加納 崇裕; 矢部 一郎; 白鳥 聡一; 後藤 秀樹; 加畑 馨; 近藤 健; 佐々木 秀直, 神経治療学, 34, 6, S223, S223, Nov. 2017
(一社)日本神経治療学会, Japanese - セフェピム脳症を来した末梢性T細胞リンパ腫の1例
長谷川祐太; 工藤彰彦; 郎朗; 江端浩; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 加納崇裕; 遠藤知之; 豊嶋崇徳, 臨床血液, 58, 12, 2017 - 多系統萎縮症様のMRI所見を呈した自己免疫性小脳炎の1例
工藤彰彦; 佐藤翔紀; 佐藤智香; 長沼亮滋; 上床尚; 白井慎一; 西村洋昭; 高橋育子; 松島理明; 加納崇裕; 矢部一郎; 佐々木秀直, 臨床神経学(Web), 57, 12, 2017
- 自己免疫性小脳失調症における新規抗神経抗体の同定
科学研究費助成事業
31 Jul. 2025 - 31 Mar. 2027
工藤 彰彦
日本学術振興会, 研究活動スタート支援, 北海道大学, 25K23892
